Obstetrics & Gynecology Science

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy

Hyejeong Hue, Kidong Kim, HyoJin Kim, Dong Hoon Suh, Jae Hong No, Yong Beom Kim

Obstet Gynecol Sci. 2019;62(4):285-289. Published online June 17, 2019
DOI: https://doi.org/10.5468/ogs.2019.62.4.285

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy

Hyejeong Hue, Kidong Kim, HyoJin Kim, Dong Hoon Suh, Jae Hong No, Yong Beom Kim

Obstetrics & Gynecology Science. 2019;62(4):285

Link1 Link2 Link3

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy

Kyung Jin Eoh, Jung-Yun Lee, Eun Ji Nam, Sunghoon Kim, Young Tae Kim, Sang Wun Kim

Journal of Korean Medical Science. 2017;32(12):2021

Link1 Link2 Link3

Neoadjuvant, adjuvant and long-term intravenous/intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy for ovarian cancer

Evgenia Halkia, Paul Sugarbaker

Journal of Peritoneum (and other serosal surfaces). 2017;

Link1 Link2

Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer

N. Onujiogu, E. Lengyel, S.D. Yamada

Gynecologic Oncology. 2008;111(3):537-539

Link1 Link2

Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma

Akshat Saxena, Terence C. Chua

Lung Cancer. 2009;66(2):269-270

Link1 Link2

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

Sharad A. Ghamande, M. Steven Piver

Journal of Surgical Oncology. 1999;72(3):162-169

Link1 Link2

Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study

Chien-Hsing Lu, Yen-Hou Chang, Wai-Hou Lee, Yi Chang, Chia-Wen Peng, Chi-Mu Chuang,

Chemotherapy. 2016;61(5):240-248

Link1 Link2

Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer

M. Steven Piver, Fernando O. Recio, Trudy R. Baker, Deborah Driscoll

Cancer. 1994;73(6):1693-1698

Link1 Link2

PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Naoual Bakrin, Clemens Tempfer, Giovanni Scambia, Michele De Simone, Boris Gabriel, Eva-Maria Grischke, Beate Rau

Pleura and Peritoneum. 2018;3(3):

Link1 Link2

Long-term survival after intraperitoneal carboplatin chemotherapy for advanced ovarian cancer

H.J. Gray, A. Kay, E.S. Wu, B.A. Goff, R.R. Urban

Gynecologic Oncology. 2018;149:206

Link1 Link2